Commentary: Screening for prostate cancer

dc.contributor.authorHeyns C.F.
dc.date.accessioned2011-05-15T16:16:40Z
dc.date.available2011-05-15T16:16:40Z
dc.date.issued2007
dc.description.abstract[No abstract available]
dc.description.versionNote
dc.identifier.citationInternational Journal of Epidemiology
dc.identifier.citation36
dc.identifier.citation1
dc.identifier.issn03005771
dc.identifier.other10.1093/ije/dyl305
dc.identifier.urihttp://hdl.handle.net/10019.1/13882
dc.subjectprostate specific antigen
dc.subjectage distribution
dc.subjectCanada
dc.subjectcancer mortality
dc.subjectcancer screening
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectCochrane Library
dc.subjectcost effectiveness analysis
dc.subjectdiagnostic value
dc.subjectearly cancer
dc.subjectearly diagnosis
dc.subjectevidence based medicine
dc.subjecthuman
dc.subjectmale
dc.subjectnote
dc.subjectpriority journal
dc.subjectprostate biopsy
dc.subjectprostate cancer
dc.subjectquality of life
dc.subjectrisk assessment
dc.subjectrisk benefit analysis
dc.subjectrisk reduction
dc.subjectsurvival time
dc.subjectsystematic review
dc.titleCommentary: Screening for prostate cancer
dc.typeNote
Files